Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate
Study will take place at Imperial College London
Read More
Tag: Peanut allergy
Aimmune’s peanut allergy med Palforzia wins EU approval
Drug becomes first treatment for peanut allergy in the EU
Read More
Aimmune’s peanut allergy med moves toward EU approval
CHMP grants Palforzia a positive opinion for the treatment of peanut allergic patients
Read More
Phase III results move Aimmune’s peanut allergy drug closer to EU market
Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance.
Read More
UK pharma Enesi links with Australian biotech Sementis
UK group Enesi Pharma has signed a deal with Australian biotech Sementis to develop solid dose versions of the latter’s lead peanut hypoallergy vaccine and its chikungunya/Zika vaccine candidates.
Read More
Aimmune’s peanut allergy drug hits PhIII targets
A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.
Read More
Promising data for Sanofi, Regeneron’s dupilumab
Sanofi and Regeneron have unveiled positive results from a mid-stage study exploring the potential of the biologic dupilumab in adults with eosinophilic esophagitis, and also signed a deal with Aimmune Therapeutics to test an experimental peanut allergy therapy.
Read More
First UK patient enrolled in peanut allergy trial
Children and adolescents in the UK with peanut allergy are among the first to enrol in a Europe-wide study investigating a new oral immunotherapy for the condition.
Read More
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
